Admin_Adham
Probiotics are promoted as natural helpers for gut health, but the scientific view is decidedly more nuanced. In fact, their benefit is well-documented for only a few indications, while the evidence for many other uses remains inconsistent. Added to that, these seemingly harmless microorganisms can pose risks for vulnerable patients.
What Are Probiotics?
Probiotics are living microorganisms that, when taken in sufficient quantities, can have a beneficial effect on health. The most used bacterial strains include members of the genus Lactobacillus — for example, Lactobacillus rhamnosus and L acidophilus — and Bifidobacterium species such as Bifidobacterium longum and B bifidum. The yeast Saccharomyces boulardii is also used therapeutically as a probiotic.
The effects are strain-, dose-, and indication-specific. Results from studies on one strain cannot automatically be transferred to other members of the same genus or to combination products. “Probiotics” are not a single therapeutic class. Evidence from individual studies can only be generalized to a limited extent.
Regulatory Classification of Probiotics in Germany
- Probiotics are not uniformly regulated. Most are classified as dietary supplements and are governed by food law — meaning they do not require drug approval and there is no legal requirement to demonstrate therapeutic effectiveness; manufacturers may make certain health claims.
- If a product is marketed or intended for treating a specific disease, it is considered a specific medical treatment and must be approved under the German Medicines Act, which requires evidence of efficacy, safety, and quality.
- If its primary effect is defined as physical or mechanical, it falls under the EU Medical Device Regulation. Such cases are rare.
Where Do Probiotics Show Benefit?
For preventing antibiotic-associated diarrhea (AAD), the most common indication, meta-analyses overall show a benefit from probiotics. However, the included studies are highly heterogeneous — depending on the class of antibiotic, the care setting, endpoints, and the specific strain used. The effect appears particularly relevant in patients at increased risk, such as patients receiving inpatient care, those on multiple medications, or those with a history of AAD.
In acute gastroenteritis in children, meta-analyses indicate that certain probiotics can shorten illness duration and sometimes reduce stool frequency. The effect is moderate and strongly dependent on the timing of administration — ideally within the first 24-48 hours — and on the strain used.
While these data mainly concern children, another indication comes into focus for extremely premature infants: the prevention of necrotizing enterocolitis. Network and umbrella analyses suggest that several strains or combinations can reduce the risk for necrotizing enterocolitis and, in some analyses, lower mortality.
Probiotics are also being studied in chronic liver disease. Meta-analyses show improvements in cognitive tests for minimal hepatic encephalopathy and in some ammonia-related parameters. Effect sizes vary depending on the comparator. Probiotics are used as adjuncts to established strategies such as lactulose or rifaximin, not as replacements for them.
There is also evidence suggesting a benefit in bacterial vaginosis. Meta-analyses indicated that probiotics — particularly as an add-on to antibiotic therapy — can reduce recurrence rates. Here, the route of administration, dose, and strain are crucial.
Where Is the Data Weak?
The American Gastroenterological Association’s guideline reaches a sober conclusion for several gastrointestinal disorders: evidence is insufficient or inconsistent for many commonly promoted indications. This includes irritable bowel syndrome. Meta-analyses showed statistically significant effects on symptoms and sometimes on quality of life, but results are heterogeneous. Different strains, dosages, study designs, and endpoints make a unified assessment difficult. In practice, this means if probiotics are used, they are best tried as a time-limited therapeutic experiment with a clearly defined evaluation point — not as an indefinite maintenance therapy without reassessment.
The situation is even more complex for inflammatory bowel disease. For many relevant endpoints, the evidence is inconsistent and sometimes contradictory. Guideline authors so far see no basis for general recommendations.
Can Probiotics Be Dangerous?
From benefit to risk: invasive infections during probiotic therapy are rare overall but can be clinically relevant, especially in vulnerable patients.
Risk factors include severe immunosuppression, central venous catheters, serious underlying disease, or significant mucosal damage. Under these conditions, what seems like a harmless supplement can become hazardous.
For S boulardii, systematic reviews have documented fungemia, particularly in intensive care settings and in patients with central venous catheters. The data show that while the overall risk is low, it rises substantially in these high-risk groups.
Bacterial bloodstream infections caused by probiotic strains such as Lactobacillus have also been reported. These are rare but occur more frequently in patients with severe comorbidities or significant immunosuppression.
Attention was drawn by the PROPATRIA study: in patients with predicted severe acute pancreatitis, probiotic treatment did not reduce infectious complications and was associated with increased mortality.
Short-bowel syndrome is another risk situation. In this setting, certain probiotic strains can lead to D-lactic acidosis with neurologic symptoms.
Conclusion: Use With Prudence
Probiotics are a sensible therapeutic component in selected indications, but only when chosen with attention to strain and indication. The most common mistake is using probiotics under the assumption that they are simply “good for the gut” — without clearly defined goals, without verified product quality, and without a structured benefit-risk assessment.
Not every strain works for every situation, and not every over-the-counter product meets the requirements for quality, dosage, and evidence needed for medically informed use.
Particularly in vulnerable patients — such as those who are immunosuppressed, have serious underlying disease, or are in intensive care — the benefit-risk balance can quickly tip. What appears to be a low-risk supplement in healthy people can rapidly become dangerous in these settings.
This story was translated from the Medscape’s German edition.
